Baseline demographics and clinical characteristics (N = 266)
| Characteristic . | Value . |
|---|---|
| Median age, y (range) | 63 (37-87) |
| Male, n (%) | 155 (58) |
| Ethnicity, n (%) | |
| Black | 53 (20) |
| Asian/Pacific Islander | 6 (2) |
| White | 190 (71) |
| Hispanic | 10 (4) |
| Other | 7 (3) |
| Median time from diagnosis, y (range) | 5.4 (0.5-22.3) |
| Ig class heavy chain, n (%) | |
| IgG | 193 (73) |
| IgA | 45 (17) |
| IgD | 2 (1) |
| Light chain only or not specified | 26 (10) |
| International Staging System stage, n (%) | |
| I | 76 (29) |
| II | 102 (38) |
| III | 81 (31) |
| ECOG performance status, n (%) | |
| 0 | 69 (26) |
| 1 | 162 (61) |
| 2 | 35 (13) |
| Cytogenetic/FISH prognostic markers, n (%) | |
| Normal/favorable | 159 (60) |
| Unfavorable | 75 (28) |
| Unknown/not done | 32 (12) |
| PN, n (%)* | |
| 0 | 60 (23) |
| 1 | 178 (67) |
| 2 | 28 (11) |
| Median creatinine clearance, mL/min (range) | 70 (16-203) |
| Median serum β2-microglobulin, mg/L (range)† | 4.3 (0.4-20.5) |
| Prior lines of therapy, median (range) | 5 (1-20) |
| ≥ 4, n (%) | 217 (82) |
| Refractory to last regimen | |
| Progressive disease on therapy | 198 (74) |
| Progressive disease within 60 d | 38 (14) |
| ≤ 25% response | 16 (6) |
| Prior agents, median (range) | 13 (3-45) |
| Bortezomib, n (%)‡ | 265 (99.6) |
| In most recent prior regimen, n (%) | 132 (50) |
| Immunomodulatory agent, n (%) | 266 (100) |
| Lenalidomide, n (%) | 249 (94) |
| Thalidomide, n (%) | 199 (75) |
| Pomalidomide, n (%) | 9 (3) |
| Corticosteroid, n (%) | 261 (98) |
| Alkylating agent, n (%) | 246 (92) |
| Stem cell transplant, n (%) | 198 (74) |
| Anthracycline, n (%) | 171 (64) |
| Characteristic . | Value . |
|---|---|
| Median age, y (range) | 63 (37-87) |
| Male, n (%) | 155 (58) |
| Ethnicity, n (%) | |
| Black | 53 (20) |
| Asian/Pacific Islander | 6 (2) |
| White | 190 (71) |
| Hispanic | 10 (4) |
| Other | 7 (3) |
| Median time from diagnosis, y (range) | 5.4 (0.5-22.3) |
| Ig class heavy chain, n (%) | |
| IgG | 193 (73) |
| IgA | 45 (17) |
| IgD | 2 (1) |
| Light chain only or not specified | 26 (10) |
| International Staging System stage, n (%) | |
| I | 76 (29) |
| II | 102 (38) |
| III | 81 (31) |
| ECOG performance status, n (%) | |
| 0 | 69 (26) |
| 1 | 162 (61) |
| 2 | 35 (13) |
| Cytogenetic/FISH prognostic markers, n (%) | |
| Normal/favorable | 159 (60) |
| Unfavorable | 75 (28) |
| Unknown/not done | 32 (12) |
| PN, n (%)* | |
| 0 | 60 (23) |
| 1 | 178 (67) |
| 2 | 28 (11) |
| Median creatinine clearance, mL/min (range) | 70 (16-203) |
| Median serum β2-microglobulin, mg/L (range)† | 4.3 (0.4-20.5) |
| Prior lines of therapy, median (range) | 5 (1-20) |
| ≥ 4, n (%) | 217 (82) |
| Refractory to last regimen | |
| Progressive disease on therapy | 198 (74) |
| Progressive disease within 60 d | 38 (14) |
| ≤ 25% response | 16 (6) |
| Prior agents, median (range) | 13 (3-45) |
| Bortezomib, n (%)‡ | 265 (99.6) |
| In most recent prior regimen, n (%) | 132 (50) |
| Immunomodulatory agent, n (%) | 266 (100) |
| Lenalidomide, n (%) | 249 (94) |
| Thalidomide, n (%) | 199 (75) |
| Pomalidomide, n (%) | 9 (3) |
| Corticosteroid, n (%) | 261 (98) |
| Alkylating agent, n (%) | 246 (92) |
| Stem cell transplant, n (%) | 198 (74) |
| Anthracycline, n (%) | 171 (64) |